Skip to content

Technology
Pipeline
About Us
News
Investors
Contact

Technology
Pipeline
About Us
News
Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 28 Results

August 7, 2024

Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis

December 5, 2023

Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine

June 23, 2021

Nasus Pharma Announces Positive Results from a Pilot Clinical Study of FMXIN002 Intranasal Powder Epinephrine Spray in

April 13, 2021

Nasus Pharma announces positive Results in Naloxone Pivotal Trial.

«1 2 34

IR Contact

Mike Moyer
LifeSci Advisors
617-308-4306
IR@nasuspharma.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Unsubscribe

Loading...

Science

Technology
Pipeline
NS002 Epinephrine
NS001 Naloxone
Publications

Company

About us
Leadership
Board of Directors
Advisory Board
Contact

Investors

Investors Overview
Press Releases
Events
SEC Filings
Corporate Governance
Stock Information
Investor FAQs

© 2026 Nasus Pharma All rights reserved

Accessibility Statement
Cookies Policy
Privacy Policy
Terms And Conditions Of Use

Scroll to Top